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Objective. Patients with neutropenic sepsis have a poor prognosis.We aimed to identify outcome predictors and generate hypotheses
how the care for these patients may be improved.Methods. All 12.352 patients admitted between 2006 and 2011 to the medical ICUs
of our tertiary university center were screened for neutropenia; out of 558 patients identified, 102 fulfilled the inclusion criteria
and were analyzed. Severity markers and outcome predictors were assessed. Results. The overall ICU mortality was 54.9%. The
severity of sepsis and the number of organ failures predicted survival of the primary septic episode (APACHE II 22.8 and 29.0;
SOFA 7.3 and 10.1, resp.). In the recovery phase, persistent organ damage and higher persistent C-reactive protein levels were
associated with a poor outcome. Blood transfusions and CMV infection correlated with an unfavorable prognosis. Ineffective initial
antibiotic therapy, fungal infections, and detection of multiresistant bacteria displayed a particularly poor outcome. Infections with
coagulase-negative staphylococci and enterococci were associatedwith a significantly highermortality and a high degree of systemic
inflammation.Conclusion. Patients with persistent organ dysfunction show an increasedmortality in the further course of their ICU
stay. Early antimicrobial treatment of Gram-positive cocci may improve the outcome of these patients.
1. Background
Many intensivists and oncologist share the often frustrating
experience of caring for patients with neutropenic sepsis:
infections are a frequent complication in leukopenic patients,
affecting an estimated 24% patients after chemotherapy for
hematologic diseases or solid organ tumors [1]. Although in
many cases the underlying disease is potentially curable, once
having to be transferred to the ICU with sepsis these patients
have a poor prognosis.
In former decades, the prognosis of these patients was
regarded as so poor that it was debatedwhether to admit them
to the ICU at all [2–5]. Subsequently, several studies tried to
identify prognosticmarkers for the outcome of these patients,
intending to help guiding the decision which patients to
admit to the ICU [6–8].
Potentially due to improved oncologic and intensive care
treatment regimes, recent studies demonstrated a reasonable
outcome of patients with neutropenic sepsis in the ICU,
documenting hospital survival rates of 50–60% [6, 9, 10].
Further data suggest that long-term prognosis of cancer
patients treated in the ICU does not differ from that of
patients who do not need ICU treatment [11, 12]. In line
with these reports today the debate whether to generally
deny these patients admission seems resolved and they are
routinely treated in ICUs.
Nevertheless, current studies addressing the prognosis of
patients with neutropenic sepsis in the ICU are scarce, and
more importantly, there are only few studies aiming to iden-
tify strategies how to improve the outcome of these patients.
Particularly little is known about the impact of the infecting
organism. Furthermore, it is unknown what determines ICU
mortality of patients who survive the initial septic episode
but remain dependent on intensive care medicine. Here we
present our results of a retrospective cohort study aiming to
clarify circumstances influencing the course of the ICU-stay,
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determining ICUmortality, and how the infecting organisms
impact outcome in these patients.
2. Methods
2.1. Patients. Neutropenic patients admitted to the medical
intensive care units of the Charite´-UniversityMedical Center,
Campus Virchow (CVK), Berlin, a university tertiary care
center, meeting the criteria of sepsis in the years 2006 to
2011, were included in the study.The study has been approved
by the ethics committee of the Charite´-University Medical
Center. According to the decision of the ethics committee, no
consent from the patients was needed due to the retrospective
character of the study.The study was conducted according to
the principles of the Declaration of Helsinki (World Medical
Association 2008).
2.2. Antibiotic Regimen. Due to the retrospective nature
of the study, the choice of antibiotics was made by the
intensivist in charge. Standard operating procedures in our
institution are based on international guidelines like those
published by the IDSA. Depending on the suspected focus
and preexisting or emerging organ system different regimens
may be installed.
2.3. Data Collection. Data were collected from the electronic
patient files. Neutropenia was defined as a neutrophil count
of <500/mm3 or a leukocyte count of <1000/mm3 in the
first 96 hours after ICU admission. Neutropenia had to
last for at least 24 hours confirmed by two independent
blood samples. Patients had to be treated for at least 24
hours on the intensive care unit to be included in the
study. Sepsis was defined in accordance to the consensus
definition by the Surviving Sepsis Campaign (SSC) guidelines
[13]. Number of blood transfusions, length of mechanical
ventilation, and extracorporeal renal support were also docu-
mented. Focus of infection as diagnosed by the intensivist in
charge and results ofmicrobiological cultureswere registered.
Coagulase-negative staphylococci and enterococci were only
classified as infecting organism if present in more than
one blood culture. Culture results were regarded as relevant
for the initial sepsis when they were acquired up to 7
days before or after ICU admission. Fungal infection was
classified following the European Organization for Research
and Treatment of Cancer (EORTC) guidelines [14]. Results
of virology examinations were also documented. Respiratory
failure was defined as intubation in the ICU, tracheotomy, or
noninvasive ventilation for at least 3 h per day. Circulatory
failure was defined by the need of vasopressors as prescribed
by the intensivist in charge. Liver failurewas defined by biliru-
bin levels > 2mg/dL or an international normalized ratio
(INR) > 2 or a prothrombin time < 50. Kidney failure was
defined according to the RIFLE classification or requirement
of renal replacement therapy [15]. Sequential organ failure
assessment score (SOFA) and Acute Physiology and Chronic
Health Evaluation Score II (APACHE II) were documented
at admission and at the time point of overcoming the sepsis
as were the different parameters for organ dysfunction.
The ICU stay was divided into two phases. The initial septic
crisis and, if it was survived, a second phase until discharge
from the ICU. The initial sepsis was considered resolved
when the patient was free of vasopressors, extubated, or
required less than 3 h of noninvasive ventilation per day, had a
decrease ofC-reactive protein (CRP) or procalcitonin ofmore
than 50% for more than 48 h, or no systemic inflammatory
response syndrome (SIRS) criteria for more than 24 h.
Our intention was to identify factors that predicted ICU
mortality if the initial crisis was overcome. 558 patients with
neutropenia were screened and 102 meeting the aforemen-
tioned sepsis criteria were included.
2.4. Statistical Analysis. Parameters were recorded as median
and interquartile range (25th–75th percentile). Categorical
variables were calculated using the chi-square test or Fisher’s
exact test. Continuous variables were calculated using the
Mann-Whitney 𝑈 test. Odds ratios were calculated using
binary logistic regression.
SPSS (Version 19, IBM) was used and graphs were
generated using GraphPad prism 5.0.
3. Results
3.1. General Patient Characteristics. Among the 12.352
patients admitted to our ICU ward between 2006 and 2011,
558 neutropenic patients were identified and 102 patients
fulfilling the criteria for neutropenic sepsis were included in
our analysis. Leukopenia was attributable to chemotherapy
(𝑛 = 79), underlying hematologic disease (𝑛 = 12), infection
(𝑛 = 4), side effect of nonchemotherapeutic drugs (𝑛 = 1),
autologous bone marrow transplantation (𝑛 = 2), and
allogenic stem cell transplantation (𝑛 = 4). The six patients
after stem cell transplantation all had a recent transplantation,
8–28 days (median 10, 5 d) prior to referral to the ICU. One
further patient after allogenic stem cell transplantation was
included in the study; however, the transplantation was
not recent and the leucopenia was attributable to infection.
Overall ICU mortality was 54.9% and 28 day mortality was
52.0%; all patients with stem cell transplantation (𝑛 = 6)
deceased during their ICU stay (Figure 1).
3.2. Model of Two Phases of the ICU Stay. In the first days
after admission to the ICU, we observed a particularly high
mortality burden, with 22.5% of all admitted patients deceas-
ing in the first 6 days. The other fatalities occurred over a
more prolonged period of time (Figure 2). In order to analyze
which patient characteristics are predictive of overcoming the
initial sepsis and which characteristics determine whether
the patient survives the entire ICU stay, we divided all ICU
stays in potentially two phases: First the initial septic episode,
followed by a recovery phase if the patient survived the initial
crisis. As defined by our criteria for overcoming the initial
sepsis, out of the total 102 patients 63 survived the initial sep-
tic crisis, while 39 patients failed to overcome the initial sepsis
and deceased during that phase. Of the 63 patients that were
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Figure 1: Context-dependent mortality of leukopenic patients
admitted to the ICU. Patients after stem cell transplantation have
an inferior prognosis. Patients with leukopenia after chemotherapy
have a significantly better ICU survival. ∗ refers to statistical
significance with 𝑝 < 0.05.
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Figure 2: Number of patients deceased per ICU day. There is a
concentration of fatalities in the first 6 days.
successfully treated for the initial sepsis, 17 patients consecu-
tively died during the recovery phase, while 46 patients were
discharged alive from the ICU (Figure 3).
3.3. Severity of Sepsis and Organ Failure Predicts Overcoming
or Not of the Initial Sepsis. The patient group that did not
overcome the initial sepsis episode was admitted to the
ICU with a significantly higher respiratory rate, higher first
documented serum lactate value and higher APACHE II
and SOFA scores as compared to the group that survived
the initial sepsis. Patients that failed to overcome the initial
crisis were more likely to be intubated and had a lower
oxygenation index. A similar proportion of both groups
received vasopressors on admission, and there was no sig-
nificant difference in the mean arterial pressure (MAP),
but the patients who did not overcome the first sepsis
episode received significantly more fluids in the first 24 h
and had a higher maximal noradrenaline dose. They more
often presented liver and renal failure, and the group with
persistent sepsis received more transfusions of erythrocytes,
platelets, and fresh frozen plasma. There was no difference
in the highest CRP as a marker for inflammation; however,
the patients who overcame the sepsis achieved lower CRP
values. Furthermore, longer duration of leukopenia prior to
ICU admission was associated with worse outcome (Table 1).
3.4. Persistent Organ Damage and High Initial CRP Predicts
Poor Outcome after Overcoming the First Sepsis. There was
no significant difference in the disease severity on admission
to the ICU between those patients who survived the initial
sepsis phase and those who died later on despite overcoming
the initial sepsis. Both groups had similar respiratory rates,
first documented serum lactate values, APACHE II and SOFA
scores when admitted to the ICU. There was no difference in
the MAP, fluids administered, or need for vasopressors in the
first 24 h. The group of nonsurvivors had a higher frequency
of circulatory failure after overcoming the initial sepsis and a
higher maximal noradrenaline dose in their total ICU stay.
The nonsurvivors where more often intubated, underwent
tracheotomy more frequently, and showed persistent lung
failure after the first sepsis episode. Likewise, renal and liver
failure was more frequent in the group with the unfavor-
able outcome. The nonsurvivors received more erythrocyte,
platelet, and fresh frozen plasma transfusions per ICU day.
Furthermore the nonsurvivors had a significantly higher CRP
in the first 10 days, which persisted in the course of their
ICU stay, indicating a higher initial and maintained extent of
inflammation (Table 2).
3.5. Impact of Microbiologic Findings on the ICU Outcome.
In 65 patients, the microbiological testing identified bacteria
and/or fungus associatedwith the initial sepsis.The identified
species were Gram-negative bacteria in 31, Gram-positive
bacteria in 27 patients, and in 12 patients, microbiology find-
ings indicated a fungal infection. Since coagulase-negative
staphylococci and enterococci are frequent contamination
of blood cultures [16, 17], positive cultures with these
bacteria were only considered indicative of an infection if
present in at least two cultures; single positive cultures were
regarded as suspicious of contamination instead of infection
and are displayed separately (Figure 4). The most common
Gram-negative microorganism was E. coli, and the most
frequent Gram-positive were coagulase-negative staphylo-
cocci. Aspergillus and other molds were the most frequently
observed fungal infections. Interestingly, among the six most
frequently identified bacteria, coagulase-negative staphylo-
cocci and Enterococcus faecium were associated with a higher
mortality (significantly higher mortality compared to all
other patients with positivemicrobiologic culture results,𝑝 =
0.039) (Figure 4). Furthermore, patients who deceased in the
ICU had significantly longer indwelling central venous lines
than patients who survived (𝑝 = 0.009) (data not shown).
In 37 patients, no causative agent for the initial sepsis
was identified. Overall, culture-positive patients had a worse
prognosis than patients without successful identification
(46.2% versus 24.3% failed to overcome the initial sepsis,
with 66% versus 35.1% total ICU mortality). Patients with
noneffective antibiotic therapy had an increased ICU mor-
tality of 81.8% (𝑛 = 11). All patients with evidence of a
fungal infection (4x Aspergillus antigen positive, 1x detection
of aspergillus in airways, 1x aspergillus in tissue biopsy,
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Figure 3: Overview of the number of analyzed patients. Of the 102 patients admitted to the ICU, 39 patients deceased in the initial sepsis
phase, while 63 patients overcame it. Of these 63 patients, 17 deceased in the ICU in the recovery phase, while 46 patients survived and were
discharged from the ICU.
Table 1: Characteristics of patients who manage to overcome the initial sepsis compared to those who decease in the initial septic episode.
Values are displayed as mean ± standard deviation; ∗/∗∗/∗ ∗ ∗ indicate level of significance.
Parameter Initial sepsis, survived (𝑛 = 63) Initial sepsis, deceased (𝑛 = 39) 𝑝 value Odds ratio
Male 65,1% (𝑛 = 41) 69,2% (𝑛 = 27) 0,666 1,207
Female 34,9% (𝑛 = 22) 30,8% (𝑛 = 12) 0,666 0,828
Age 55,1 ± 14,9 (𝑛 = 63) 54,6 ± 11,9 (𝑛 = 39) 0,613 0,997
Days in the ICU 16,9 ± 17,0 (𝑛 = 63) 8,5 ± 7,6 (𝑛 = 39) 0,020 0,944∗∗
Duration prior to leukopenia 10,8 ± 16,3 (𝑛 = 52) 17,8 ± 18,5 (𝑛 = 36) 0,012 1,024
Respiratory frequency 26,1 ± 7,6 (𝑛 = 63) 29,5 ± 8,0 (𝑛 = 39) 0,032 1,058∗
First Lactate (mg/dL) 23,2 ± 19,3 (𝑛 = 63) 36,4 ± 37,8 (𝑛 = 39) 0,237 1,017∗
APACHE II on admission 22,8 ± 8,4 (𝑛 = 62) 29,0 ± 11,2 (𝑛 = 39) 0,003 1,069∗∗
SOFA on admission 7,3 ± 4,8 (𝑛 = 62) 10,1 ± 5,4 (𝑛 = 39) 0,011 1,115∗
Intubation 55,6% (𝑛 = 35) 89,7% (𝑛 = 35) 0,000 7,000∗
Lowest oxygenation index 112,8 ± 80,2 (𝑛 = 44) 81,4 ± 44,4 (𝑛 = 34) 0,035 0,99
Vasopressors in the first 24 h 63,5% (𝑛 = 40) 61,5% (𝑛 = 24) 0,843 0,92
Maximal noradrenaline dose (mg/h) 2,9 ± 3,2 (𝑛 = 45) 5,7 ± 3,7 (𝑛 = 36) 0,000 1,280∗∗
Fluid administration in the first 24 h (mL) 6710,8 ± 2527,0 (𝑛 = 63) 8960,5 ± 4790,8 (𝑛 = 39) 0,020 1,000∗∗
MAP first 24 h 56,1 ± 14,4 (𝑛 = 47) 55,1 ± 11,7 (𝑛 = 31) 0,617 0,994
Liver failure on admission 42,9% (𝑛 = 27) 66,7% (𝑛 = 26) 0,019 2,667∗
Lowest bilirubin 1,4 ± 1,7 (𝑛 = 63) 2,4 ± 2,8 (𝑛 = 39) 0,023 1,249∗
Lowest INR 1,2 ± 0,17 (𝑛 = 73) 1,4 ± 0,2 (𝑛 = 39) 0,000 49,677∗∗∗
Lowest urine output (mL/24 h) 1303,5 ± 1068,6 (𝑛 = 63) 540,1 ± 693,0 (𝑛 = 39) 0,000 0,999∗∗∗
Kidney failure 52,4% (𝑛 = 33) 79,5% (𝑛 = 31) 0,006 3,523∗∗
Renal replacement therapy 33,3% (𝑛 = 21) 71,8% (𝑛 = 28) 0,000 5,091∗∗∗
GCS on admission 12,7 ± 3,9 (𝑛 = 63) 13,1 ± 3,3 (𝑛 = 39) 0,876 1,031
GCS highest 14,6 ± 1,3 (𝑛 = 63) 13,2 ± 3,3 (𝑛 = 39) 0,002 0,735∗
Erythrocyte concentrates (units/day) 0,6 ± 1,1 (𝑛 = 63) 1,1 ± 0,9 (𝑛 = 39) 0,000 1,752∗
Platelet concentrates (units/day) 0,6 ± 0,6 (𝑛 = 63) 1,0 ± 0,6 (𝑛 = 39) 0,000 2,773∗∗
Fresh frozen plasma (units/day) 0,5 ± 0,8 (𝑛 = 63) 2,2 ± 2,8 (𝑛 = 39) 0,000 2,763∗∗∗
CRP highest first 10 days (mg/dL) 30,6 ± 9,9 (𝑛 = 63) 34,8 ± 16,8 (𝑛 = 39) 0,214 1,026
CRP lowest (mg/dL) 10,2 ± 8,7 (𝑛 = 63) 19,1 ± 10,8 (𝑛 = 39) 0,000 1,100∗∗∗
Persistent leukopenia 36,5% (𝑛 = 23) 82,1% (𝑛 = 32) 0,000 7,950∗∗∗
4x Candida species in blood culture, 2x Pneumocystis jirovecii
in airways, and 1 Saccharomyces species in blood culture) as
cause of the initial sepsis deceased in the ICU (𝑛 = 13).
Proof of infection or colonizationwithmultiresistant bacteria
during the total ICU treatment was associated with higher
mortality (81.8%, 𝑛 = 22).
A total of 39 patients were tested for active cytomegaly
virus (CMV) replication during their ICU stay. Of these
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Figure 4: Microbiologic findings in the initial sepsis phase. (a) Overview of the pathogens identified in the initial sepsis. (b) The most
commonly identified Gram-negative bacteria (displayed are the bacteria that were observed in at least 2 patients). (c) The most frequently
found Gram-positive bacteria (displayed are the bacteria that were observed in at least 2 patients). (d) Fungi observed in the microbiologic
diagnostic. (e) The mortality of the 6 most frequently found bacteria.
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Table 2: Comparison of patients in the recovery phase after overcoming the initial sepsis. Values are displayed as mean ± standard deviation;
∗/∗∗ indicate level of significance.
Parameter Recovery phase, survived (𝑛 = 46) Recovery phase, deceased (𝑛 = 17) 𝑝 value Odds ratio
Male 65,2% (𝑛 = 30) 64,7% (𝑛 = 11) 0,970 0,978
Female 34,8% (𝑛 = 16) 35,3% (𝑛 = 6) 0,970 1,023
Age 57,0 ± 13,9 (𝑛 = 46) 50,1 ± 16,7 (𝑛 = 17) 0,152 0,969
Days in the ICU 13,3 ± 13,5 (𝑛 = 46) 26,7 ± 21,6 (𝑛 = 17) 0,004 1,047∗
Duration prior to leukopenia 9,0 ± 15,8 (𝑛 = 46) 16,2 ± 17,3 (𝑛 = 17) 0,086 1,024
Respiratory frequency 25,7 ± 7,8 (𝑛 = 46) 27,4 ± 7,1 (𝑛 = 17) 0,243 1,031
First lactate (mg/dL) 21,0 ± 15,6 (𝑛 = 46) 29,0 ± 26,5 (𝑛 = 17) 0,368 1,02
APACHE II on admission 22,3 ± 7,8 (𝑛 = 45) 24,0 ± 9,9 (𝑛 = 17) 0,837 1,025
SOFA on admission 7,0 ± 4,7 (𝑛 = 45) 8,1 ± 5,2 (𝑛 = 17) 0,462 1,045
Intubation 39,1% (𝑛 = 18) 100% (𝑛 = 17) 0,000 53,919∗∗
Lowest oxygenation index 126,7 ± 94,2 (𝑛 = 27) 90,8 ± 45,3 (𝑛 = 17) 0,185 0,991
Tracheotomy 21,7% (𝑛 = 10) 64,7% (𝑛 = 11) 0,001 6,600∗∗
Lung failure after initial crisis 45,7% (𝑛 = 21) 94,1% (𝑛 = 16) 0,001 19,048∗∗
Vasopressors in the first 24 h 56,5% (𝑛 = 26) 82,4% (𝑛 = 14) 0,059 3,59
Maximal Noradrenaline dose (mg/h) 1,9 ± 1,6 (𝑛 = 28) 4,7 ± 4,2 (𝑛 = 17) 0,009 1,466∗
Fluid administration in the first 24 h (mL) 6670,7 ± 2375,0 (𝑛 = 46) 6819,5 ± 2977,2 (𝑛 = 17) 1,000 1
MAP first 24 h 56,0 ± 15,2 (𝑛 = 35) 56,6 ± 12,0 (𝑛 = 12) 0,643 1,003
Circulatory failure after initial crisis 4,3% (𝑛 = 2) 23,5% (𝑛 = 4) 0,021 6,769∗
Liver failure on admission 43,5% (𝑛 = 20) 41,2% (𝑛 = 7) 0,870 0,91
Lowest bilirubin 1,3 ± 1,2 (𝑛 = 46) 1,8 ± 2,6 (𝑛 = 17) 0,963 1,185
Lowest INR 1,2 ± 0,2 (𝑛 = 46) 1,2 ± 0,2 (𝑛 = 17) 0,871 0,792
Liver failure after initial crisis 37% (𝑛 = 17) 58,8% (𝑛 = 10) 0,120 2,437
Lowest urine output (mL/24 h) 1548,5 ± 1089,2 (𝑛 = 46) 640,5 ± 669,4 (𝑛 = 17) 0,001 0,999∗∗
Kidney failure 41,3% (𝑛 = 19) 82,4% (𝑛 = 14) 0,004 6,632∗∗
Renal replacement therapy 21,7% (𝑛 = 10) 64,7% (𝑛 = 11) 0,001 6,600∗∗
GCS on admission 12,7 ± 4,1 (𝑛 = 46) 12,8 ± 3,4 (𝑛 = 17) 0,871 1,005
GCS highest 15,0 ± 0,1 (𝑛 = 46) 13,7 ± 2,4 (𝑛 = 17) 0,000 0,070∗
Erythrocyte concentrates (units/day) 0,6 ± 1,2 (𝑛 = 46) 0,7 ± 0,5 (𝑛 = 17) 0,003 1,111
Platelet concentrates (units/day) 0,5 ± 0,7 (𝑛 = 46) 0,8 ± 0,5 (𝑛 = 17) 0,008 2,002
Fresh frozen plasma (units/day) 0,4 ± 0,9 (𝑛 = 46) 0,7 ± 0,6 (𝑛 = 17) 0,000 1,567
CRP highest in the first 10 days (mg/dL) 28,9 ± 8,8 (𝑛 = 46) 35,3 ± 11,5 (𝑛 = 17) 0,068 1,073∗
CRP lowest (mg/dL) 8,2 ± 6,5 (𝑛 = 46) 15,6 ± 11,4 (𝑛 = 17) 0,008 1,106∗∗
Persistent leukopenia 30,4% (𝑛 = 14) 52,9% (𝑛 = 9) 0,100 2,571
39 patients, 6 had active CMV replication, and all 6 patients
deceased during their ICU treatment (data not shown).
4. Discussion
In this retrospective cohort study, we examined patients with
neutropenic sepsis admitted to amedical ICU.We report here
total mortality and survival times at the ICU and assessed
different predictors of ICU mortality in the different phases
of the ICU stay. Additionally, we analyzed microbiologic
findings and their association with the clinical course.
The overall ICU-mortality in our cohort was 54.9%.
While significantly higher mortality rates were reported for
neutropenic patients in former decades [18], Legrand et al.
[10] recently presented a comparable mortality rate of 49.8%
in their cohort of patients with neutropenic sepsis. A group
of cancer patients with various diagnoses examined by Pene´
et al. [19] showed an ICU-mortality of 52.7%, which is also in
the same range as ours, although not only septic patients were
examined. Mokart et al. [20] found a surprisingly low ICU-
mortality of 23% comparable to the numbers reported for
infected patients without neutropenia, for example, in a large
multicenter trial by Vincent in 2008 [21]. Potential differences
in the study populations may account for the reported
variability in survival, since factors such as the reason for
neutropenia may exert a strong impact on outcome.
In our study, we chose to adopt a two-phase model to
analyze our cohort of patients. While many patients died
during the initial septic shock episode, a significant number
of patients succumbed later after they had overcome the
primary sepsis phase. We believe that it is more useful to
assess these patient groups separately instead of analyzing
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them together, since the factors predicting outcome in the
initial sepsis and the recovery phase may differ substantially.
Once the first sepsis is overcome, persistent organ failure
is associated with poor survival, regardless of whether it was
respiratory, circulatory, renal, or hepatic failure. Additionally,
a high initial CRP and higher persistent CRP levels indicated
poor outcome, stressing the importance of successful source
control and adequate antibiotic therapy in early in the course
by prescribing adequate antibiotic regimens and choosing
adequate doses and taking other actions aiming at source
control like replacement of central lines or removing them
if possible. Another possible explanation might be that
an elevated immune response in the patients with higher
markers of inflammation may contribute to worse prognosis.
Unlike the patients that were lost during the initial sepsis,
the illness severity scores at admission had no impact on
survival once the first sepsis episode was resolved. Onemight
suggest that any organ failure remaining after successful
therapy of the initial insult leaves the patientmore susceptible
to a second hit, most often secondary infection. A state of
immune paralysis related to any failing organ system may
be causally accused as well as prolonged immobilization or
a state of persisting catabolic metabolism. Our data do not
allow drawing a safe conclusion regarding a definite cause.
Duration of neutropenia is often considered amain factor
determining the prognosis of patients with neutropenic
sepsis [6, 22]. While duration of prior neutropenia was
associated with an unfavorable outcome in our study, the
persistence of neutropenia was not detected as a predictive
factor once the initial sepsis was overcome. Possibly our
study was underpowered to detect the impact of resolving
neutropenia or the impact of leukocyte recovery is overplayed
by other factors such as persistent need for organ support.
Unexpectedly, patients with a positive microbiological
culture result showed a significantly higher mortality than
those patients with negative results. To us themost reasonable
explanation is that negative cultures point to an adequate
selection of antibiotics prior to ICU-admission on the ward,
since all patients were already under antibiotic treatment
when admitted to the ICU. Another possible explanation
is that culture-negative patients may have suffered from a
SIRS of noninfectious origin, which might carry a better
prognosis depending on etiology. Furthermore, it may be
reasonable to assume that the likelihood of identifying a
causativemicroorganism increaseswith extent and severity of
the infection. Additionally, negative cultures after admission
to the ICU may reflect successful coverage of the culprit
organism by the antimicrobial treatment given prior to ICU
admission. As expected, patients with an inadequate initial
antimicrobial therapy had a significantly higher mortality,
which is consistent with previous reports [23–25].
Interestingly, infections with coagulase-negative staphy-
lococci (CNS) and Enterococcus spp. showed a higher degree
of systemic inflammation mirrored in a significantly higher
CRP level and a higher ICU mortality. In comparison,
Pseudomonas aeruginosa was isolated only in a minority
of four patients. Our data would thus suggest calculated
treatmentwith glycopeptides or other antibioticswith activity
against CNS and Enterococcus species.
Most of the isolated bacterial pathogens are part of
the flora of gut and skin. This suggests a potentially cru-
cial role of translocation through gastrointestinal mucosa
due to mucositis on one hand and catheter-related infec-
tions on the other hand. In patients who succumbed to
the initial sepsis, the time elapsed since the last replace-
ment of central venous lines was significantly longer.
Consistent with this observation, indwelling central line
removal has previously been associated with better out-
come [10]. Consequently, strategies for preventing bacterial
translocation and strict removal or replacement of cen-
tral venous lines after ICU admission should be advo-
cated.
Notably, all patients who tested positive for active CMV
infection deceased during their ICU stay. It remains unclear
whether this active replication is only a marker of disease
severity or plays a causative role in worsening prognosis
either due to immunomodulation by or virulence of the virus
itself. Controlled studies are needed to determine whether
consequent prophylaxis or treatmentmay improve the course
of illness in this subset of patients.
Two subgroups of patients had a particularly poor out-
come: all patients after stem cell transplantation and all
patients with a fungal infection on admission died in the
course of their ICU stay. These observations are in line with
previous publications that reported a very poor prognosis of
patients after stem cell transplantation or neutropenic fungal
infection in the ICU [8, 26].
In our cohort, patients who survived the sepsis received
fewer blood transfusions. It is impossible to differentiate
whether the higher number of transfusions is an indicator of
a more severe disease, or if transfusions account for a worse
prognosis. Problems with transfusion-associated lung injury
and transfusion-associated inflammation are well known,
and recent studies showed the benefit of restrictive transfu-
sion strategies in different populations of ICU-patients [27,
28].
The main limitations of this study are its retrospective
character and the fact that it is a single center study.Therefore,
it is only hypothesis-generating and underscores the urgent
need for prospective studies to further identify successful
interventions in this subset of patients.
5. Conclusions
In patients with neutropenic sepsis, prognosis of the initial
insult is determined mainly by severity of multiple organ
failure. A significant proportion of patients who overcome
the initial sepsis die in the further course of their ICU stay.
In particular, patients with remaining organ dysfunction
are at increased risk. Microbiological findings imply that
all measures should be undertaken to preserve integrity of
the gastrointestinal mucosa, for example, by early enteral
feeding and central venous access should be replaced or
removed following ICU admission. Adding antimicrobials
with activity against Gram-positive cocci resistant to beta-
lactam antibiotics early in the course of disease may have a
significant impact on outcome.
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